Y-mAbs Therapeutics (YMAB) News Today $5.09 -0.07 (-1.36%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 23 at 9:18 AM | nasdaq.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday.March 22 at 8:46 AM | marketbeat.comY-mAbs Therapeutics price target lowered to $12 from $22 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.com4YMAB : Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 21, 2025 | benzinga.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Sells $20,368.40 in StockY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) CEO Michael J. Rossi sold 3,917 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.20, for a total value of $20,368.40. Following the completion of the transaction, the chief executive officer now directly owns 137,083 shares in the company, valued at $712,831.60. This trade represents a 2.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 SharesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 SharesMarch 12, 2025 | insidertrades.comBearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimatesMarch 9, 2025 | finance.yahoo.comYMAB FY2025 EPS Forecast Lowered by Cantor FitzgeraldY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Y-mAbs Therapeutics in a research note issued to investors on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will postMarch 8, 2025 | marketbeat.comQ1 EPS Estimate for Y-mAbs Therapeutics Boosted by AnalystY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities researchers at Brookline Capital Management lifted their Q1 2025 earnings estimates for Y-mAbs Therapeutics in a note issued to investors on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver now anticipates that tMarch 8, 2025 | marketbeat.comWedbush Equities Analysts Lower Earnings Estimates for YMABY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Analysts at Wedbush reduced their Q1 2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Wedbush analyst D. Nierengarten now anticipates that tMarch 8, 2025 | marketbeat.comTruist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00Truist Financial dropped their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday.March 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at Bank of AmericaBank of America lowered their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday.March 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $7.00 Price Target at Morgan StanleyMorgan Stanley reduced their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday.March 6, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For Y-mAbs TherapeuticsMarch 5, 2025 | benzinga.comY-mAbs Therapeutics price target lowered to $12 from $14 at BofAMarch 5, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comY-mAbs Therapeutics' (YMAB) "Outperform" Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday.March 4, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | finanznachrichten.deY-mAbs Shares Fall After Outlook, 4Q Revenue MissMarch 4, 2025 | marketwatch.comY-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c)March 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $105.76MMarch 4, 2025 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years agoMarch 4, 2025 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Misses Expectations By $0.02 EPSY-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%.March 4, 2025 | marketbeat.comY-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsMarch 4, 2025 | globenewswire.comY-mAbs announces publication of Phase 2 interim results on naxitamabMarch 3, 2025 | markets.businessinsider.comY-mAbs Announces Publication of Phase 2 Interim Results in Nature CommunicationsMarch 3, 2025 | globenewswire.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Buy" from BrokeragesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strongMarch 1, 2025 | marketbeat.comY-mAbs Therapeutics (YMAB) to Release Quarterly Earnings on TuesdayY-mAbs Therapeutics (NASDAQ:YMAB) will be releasing earnings before the market opens on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=668872)February 25, 2025 | marketbeat.comY-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025February 20, 2025 | globenewswire.comYMAB Stock Touches 52-Week Low at $5.69 Amid Market ChallengesFebruary 12, 2025 | msn.comY-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences ConferenceFebruary 6, 2025 | globenewswire.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned an average rating of "Buy" from the ten research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy ratingFebruary 4, 2025 | marketbeat.comY-mAbs Therapeutics presents translational pharmacokinetics data of GD2-SADAJanuary 31, 2025 | markets.businessinsider.comY-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual MeetingJanuary 31, 2025 | globenewswire.comYMAB stock touches 52-week low at $6 amid challenging yearJanuary 28, 2025 | msn.comY-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical TrialsJanuary 24, 2025 | seekingalpha.comResearch Analysts Offer Predictions for YMAB FY2025 EarningsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the compJanuary 22, 2025 | marketbeat.comY-Mabs Therapeutics (YMAB) Receives a Buy from H.C. WainwrightJanuary 13, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Receives a Buy from Truist FinancialJanuary 13, 2025 | markets.businessinsider.comY-mAbs Therapeutics Updates on Business and Clinical TrialsJanuary 13, 2025 | tipranks.comHC Wainwright Reiterates Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comJonesTrading Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB)January 11, 2025 | markets.businessinsider.comY-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Friday.January 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc.: Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitJanuary 10, 2025 | finanznachrichten.deY-mAbs Therapeutics appoints Gentilcore as SVP, head of DANYELZA unitJanuary 10, 2025 | markets.businessinsider.comY-mAbs Therapeutics announces milestones for 2025January 10, 2025 | markets.businessinsider.comCorrecting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesJanuary 10, 2025 | globenewswire.com Remove Ads Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Media Mentions By Week YMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼-0.010.68▲Average Medical News Sentiment YMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼63▲YMAB Articles Average Week Remove Ads Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCKT News Today XNCR News Today ZYME News Today XERS News Today PAHC News Today GYRE News Today OCS News Today REPL News Today COGT News Today DAWN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
